Multiple Sclerosis Clinic Scenario: Best Practices for Synergistic Care From Diagnosis and Onward

Multiple Sclerosis Clinic Scenario: Best Practices for Synergistic Care From Diagnosis and Onward
0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s)
Launch Date:
October 29, 2015
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

This activity is intended for neurologists, nurses, nurse practitioners, physician assistants, and also other healthcare professionals who are members of the multidisciplinary team who care for patients with MS.

Relevant Terms:

Multiple Sclerosis

Stephen Krieger, MD

Stephen Krieger, MD
Associate Professor of Neurology
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Director, Neurology Residency Program
Icahn School of Medicine at Mount Sinai
New York, NY

Stephen Krieger, MD, joined The Corinne Goldsmith Dickinson Center (CGDC) for Multiple Sclerosis (MS) as a fellow in MS after completing his neurology residency training at Mount Sinai.  Dr. Krieger was the recipient of a 2006 American Academy of Neurology (AAN) Scholarship and received a Sylvia Lawry Fellowship in clinical research from the National Multiple Sclerosis Society. He graduated summa cum laude from Columbia College, and received his MD degree from Yale University. He completed his medical internship at St. Vincent’s Hospital, Manhattan, and is board certified in neurology by the American Board of Psychiatry and Neurology (ABPN).
Dr. Krieger has a clinical practice at the CGDC for MS and is participating in several MS clinical trials, including oral therapies and monoclonal antibodies. He has worked on clinical trials for fingolimod, alemtuzumab, daclizumab, rituximab, BG-12 (oral fumarate), and fampridine. In addition to his clinical work, Dr. Krieger has an academic appointment as Associate Professor of Neurology at the Mount Sinai School of Medicine, where he is Director of the Neurology Residency Training Program. He has also served as Director of the Brain and Behavior seminar series for the medical school. Dr. Krieger is on several advisory boards and steering committees in the field of MS, and is an active member of the AAN, by whom he was given the A.B. Baker Teaching Recognition Award in 2010. He has presented work at AAN, CMSC, ACTRIMS and ECTRIMS. Dr. Krieger is author of numerous review articles and has lectured nationally about MS, with an emphasis on emerging therapies. 
1. Analyze criteria for initiating and changing disease-modifying therapy for multiple sclerosis (MS) based on the latest biologic evidence and clinical findings
2. Critically assess individuals with MS for disease-related symptoms and affective disorders as well as treatment-related adverse events and safety risks as a means of improving shared therapeutic decision-making
3. Explore the different manifestations of progressive MS to assist in the development of personalized care plans supported by multidisciplinary teams
4. Provide ongoing follow-up and management of MS and MS-related symptoms, guide and support problem solving and decision making, and communicate and promote self-care strategies to enhance patient wellness

Program Description  
The management of multiple sclerosis (MS) typically follows 3 pathways: (1) symptom management; (2) relapse management; and (3) disease management using disease-modifying therapies (DMTs). This interactive case study allows learners to use evidence-based content to follow a patient from initial diagnosis and initial therapy to follow-up visits and add-on therapy. The case study contains short video clips that reinforce/provide support for clinical decisions with an emphasis on shared-decision making.
Conflict of Interests Disclosure Policy
The CMSC, NPA, and Haymarket Medical Education in accordance with ACCME, ANCC, and industry guidelines, have asked all faculty members to disclose any relevant financial relationships they or their significant other have with business and industry within the previous 12 months. Additionally, all faculty have been asked to disclose to learners any discussion of off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States and investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.  All presentations were reviewed by an independent clinician with no disclosed relevant financial relationships for the purpose of resolution of any identified conflict of interest and a determination of evidence-base and fair balance.
Faculty Disclosures:
Dr. Krieger is a consultant for Acorda Therapeutics, Inc., Bayer, Biogen, EMD Serono, Inc., Genentech, Inc., Genzyme Corporation, Novartis, and Questcor/Mallinckrodt. He is on the speakers’ bureau of Biogen.
Accredited Provider Disclosures:
June Halper, MSN, ACNP, has disclosed the following financial relationship: consultant for non-clinical subject matter: Biogen. Laurie Scudder, DNP, NP, has served as Nurse Planner for this activity. She has declared no relevant financial relationships. All other individuals at the Consortium of Multiple Sclerosis Centers and Nurse Practitioner Alternatives staff involved in the planning and content review have disclosed no relevant financial relationships. 
Publishing Staff Disclosures:
Haymarket Medical Education staff involved in the planning and content review have disclosed no relevant financial relationships. 
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Consortium of Multiple Sclerosis Centers (CMSC), Nurse Practitioner Alternatives (NPA), and Haymarket Medical Education (HME). The CMSC is accredited by the ACCME to provide continuing medical education for physicians.

Nurse Practitioner Alternatives (NPA) is accredited as a provider of continuing nurse education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement
The CMSC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NPA designates this enduring material for a maximum of 0.50 continuing nursing education credits. Code: CMSC-H CLSCEN 2015
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. CMSC, NPA, and HME do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CMSC, NPA, and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

If you have any questions relating to the accreditation of this activity, please contact Lisa DeSantis at 
This educational activity is jointly provided by the Consortium of Multiple Sclerosis Centers, Nurse Practitioner Alternatives, and Haymarket Medical Education.
This activity is supported by an educational grant from Biogen. 
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
Privacy Policy
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.